414 related articles for article (PubMed ID: 23266443)
1. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
2. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
3. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
Vinayagam R; Sibson DR; Holcombe C; Aachi V; Davies MP
BMC Cancer; 2007 Jul; 7():131. PubMed ID: 17640362
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptors β1 and β2 are associated with distinct responses of estrogen receptor α-positive breast carcinoma to adjuvant endocrine therapy.
Dhimolea E; Tiniakos DG; Chantzi ΝΙ; Goutas N; Vassilaros SD; Mitsiou DJ; Alexis ΜN
Cancer Lett; 2015 Mar; 358(1):37-42. PubMed ID: 25524554
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma.
Chakravarty D; Srinivasan R; Ghosh S; Gopalan S; Rajwanshi A; Majumdar S
Int J Gynecol Cancer; 2007; 17(4):905-13. PubMed ID: 17309672
[TBL] [Abstract][Full Text] [Related]
6. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
7. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
8. Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis.
Chakravarty D; Gupta N; Goda JS; Srinivasan R; Patel FD; Dhaliwal L
Acta Histochem; 2010 Jul; 112(4):355-63. PubMed ID: 19446313
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
11. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
12. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
15. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
Engelsen IB; Stefansson IM; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2008 Nov; 199(5):543.e1-7. PubMed ID: 18599012
[TBL] [Abstract][Full Text] [Related]
16. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
Powell MA; Mutch DG; Rader JS; Herzog TJ; Huang TH; Goodfellow PJ
Cancer; 2002 Jun; 94(11):2941-52. PubMed ID: 12115383
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
Ino K; Yoshida N; Kajiyama H; Shibata K; Yamamoto E; Kidokoro K; Takahashi N; Terauchi M; Nawa A; Nomura S; Nagasaka T; Takikawa O; Kikkawa F
Br J Cancer; 2006 Dec; 95(11):1555-61. PubMed ID: 17117179
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.
Tergas AI; Buell-Gutbrod R; Gwin K; Kocherginsky M; Temkin SM; Fefferman A; Lengyel E; Yamada SD
Gynecol Oncol; 2012 Nov; 127(2):316-20. PubMed ID: 22835717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]